2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2639

Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 2640

Performance of Berden’s Classification and ANCA Renal Risk Score for the Prediction of End-Stage Renal Disease in ANCA-associated Vasculitis
Abstract Number: 2641

Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Abstract Number: 2642

ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA
Abstract Number: 2643

Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre
Abstract Number: 2644

Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis
Abstract Number: 2645

The Anteromedial Ultrasound Examination of the Large Supraaortic Vessels Identifies Higher Rates of Large Vessel Involvement Than Previous Reported in Patients with Giant Cell Arteritis
Abstract Number: 2646

Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data
Abstract Number: 2647

Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study
Abstract Number: 2648

Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy: A Retrospective, Single Center Experience over a 21 Years’ Period
Abstract Number: 2649

Comparison of Biopsy Proven Giant Cell Arteritis in North America and South Europe: A Population-Based Study
Abstract Number: 2650

Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration
Abstract Number: 2651

Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?
Abstract Number: 2652

Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up
Abstract Number: 2653

Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].